Better access, stewardship practices by pharma companies needed for promising new antibiotics

The article conveys how the present-day pipeline for antimicrobial drugs is falling short against the growing prevalence of superbugs. It then pinpoints four key takeaways from the report:

• The lack of concrete action plans for drug registration in lower- and middle-income countries by pharma companies.

• The lack of affordability and stewardship planning.

• The promising trend of pharma companies initiating or running paediatric trials of antimicrobials prior to market approval.

• The need for further collaboration to scale access efforts.

“We have a small, but effective, arsenal in the race to combat drug resistance,” the article quotes Jayasree K. Iyer, CEO of the Foundation as saying. “The difference between us winning or losing this race depends on how companies enable access to people living on the frontlines of drug resistance.”